GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (TSXV:NRX) » Definitions » Shares Outstanding (EOP)

NurExone Biologic (TSXV:NRX) Shares Outstanding (EOP) : 70.52 Mil (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. NurExone Biologic's shares outstanding for the quarter that ended in Sep. 2024 was 70.52 Mil.

NurExone Biologic's quarterly shares outstanding increased from Jun. 2024 (67.16 Mil) to Sep. 2024 (70.52 Mil). It means NurExone Biologic issued new shares from Jun. 2024 to Sep. 2024 .

NurExone Biologic's annual shares outstanding increased from Dec. 2022 (42.86 Mil) to Dec. 2023 (48.25 Mil). It means NurExone Biologic issued new shares from Dec. 2022 to Dec. 2023 .


NurExone Biologic Shares Outstanding (EOP) Historical Data

The historical data trend for NurExone Biologic's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Shares Outstanding (EOP) Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23
Shares Outstanding (EOP)
42.38 42.86 48.25

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.25 48.25 65.82 67.16 70.52

Competitive Comparison of NurExone Biologic's Shares Outstanding (EOP)

For the Biotechnology subindustry, NurExone Biologic's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NurExone Biologic's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's Shares Outstanding (EOP) falls into.


;
;

NurExone Biologic Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


NurExone Biologic  (TSXV:NRX) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


NurExone Biologic Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


NurExone Biologic Business Description

Traded in Other Exchanges
Address
1 Adelaide St. East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing innovative, biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the global biopharmaceutical industry for other diseases and indications.
Executives
James Angus Wilson (bilkstys-) Richardson 10% Security Holder, Director, Senior Officer

NurExone Biologic Headlines

No Headlines